Rosen Law Firm Urges Reckitt Investors to Join Class Action Lawsuit

On June 8, 2025, the Rosen Law Firm, a prominent global investor rights law firm, announced the filing of a class action lawsuit on behalf of individuals who purchased American Depositary Shares (ADSs) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021, and July 28, 2024. The law firm is urging affected investors to secure legal counsel before the pivotal deadline of August 4, 2025, for those wishing to serve as lead plaintiff in the case.

This class action stems from allegations that Reckitt neglected to disclose critical information regarding the risks associated with its cow’s milk-based formula, Enfamil, particularly for preterm infants. According to the lawsuit, Reckitt's management did not inform investors that these products could increase the risk of necrotizing enterocolitis (NEC) in vulnerable infants. Consequently, claims have emerged that the company's optimistic statements regarding its business and future prospects were misleading and lacked a reasonable basis.

The significance of this lawsuit is amplified by the broader context of Reckitt's market position and financial health. As noted by Laurence Rosen, founding partner of the Rosen Law Firm, investors who purchased Reckitt ADSs during the class period may be entitled to compensation without incurring any out-of-pocket fees through a contingency fee arrangement. The firm has a storied history, having secured substantial settlements in similar class action cases, including the largest securities class action settlement against a Chinese company at the time.

Experts underscore the importance of such litigation in holding corporations accountable. Dr. Emily Carter, Professor of Business Law at Columbia University, states, "Class actions serve not just to recover losses for investors but also to reinforce corporate transparency and accountability."

The implications of the case extend beyond financial ramifications. As highlighted in a report by the World Health Organization, infant formula safety is a critical public health issue. The potential link between Reckitt’s products and serious health risks raises questions about regulatory oversight and corporate responsibility in the food and consumer goods sector.

Investors are advised to exercise caution and consider their options. The Rosen Law Firm encourages those affected to visit their dedicated webpage for further information or to initiate contact through their toll-free number. Legal representatives emphasize that joining the lawsuit does not preclude investors from participating in future recoveries, even if they choose not to act as lead plaintiffs.

As the deadline approaches, the case is likely to garner further attention, reflecting ongoing concerns regarding the safety of nutritional products for infants and the responsibilities of companies in disclosing risks associated with their products. The outcome of this lawsuit could have lasting implications for Reckitt Benckiser Group PLC and its investors, as well as for regulatory practices within the industry moving forward.